<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="164907">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02013297</url>
  </required_header>
  <id_info>
    <org_study_id>ET13-064</org_study_id>
    <nct_id>NCT02013297</nct_id>
  </id_info>
  <brief_title>Study of SBRT Efficacy on Intra and Extra -Cranial Tumors or Metastasis in Pediatrics Population (SBRT Pediatrics)</brief_title>
  <acronym>SBRT</acronym>
  <official_title>Hypofractionated Stereotactic Radiation Treatments (SBRT) on Children, Teenagers and Young Adults Malignant Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Leon Berard</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of hypofractionated stereotactic
      radiation treatments (SBRT) on children, teenagers and young adults malignant tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SBRT (Stereotactic Body Radiation Therapy) is a radiotherapy treatment which involves the
      delivery of a single high dose radiation treatment or a few fractionated radiation
      treatments (usually up to 5). A high potent biological dose of radiation is delivered to the
      tumor improving the cure rates for the tumor, in a manner previously not achievable by
      standard conventional radiation therapy.

      For adult patients, the &quot;Haute Authorité de Santé&quot; (HAS) validates some indications for this
      treatment which are the followings :

        -  Few primary or secondary brain tumors, which cannot be surgically removed

        -  Spinal tumors

        -  Primary bronchopulmonary tumors T1 T2 N0 M0 and pulmonary metastasis with slow growth
           and controled primary tumor.

      For pediatrics patients, no indication is now validated by HAS. Indications validated for
      adults are rare in pediatrics but not exceptional, and in such cases efficient alternative
      treatments does not exist.

      In consequence, and regarding the good results obtained in adult patients, it seems very
      important to validate the efficacy of this treatment on pediatrics population
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Efficacy of SBRT assessed 6 months after treatment</measure>
    <time_frame>6 months after inclusion</time_frame>
    <safety_issue>No</safety_issue>
    <description>The treatment efficacy is assessed by calculation of local control rate of irradiated locations according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria (complete response + partial response + stable disease)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of SBRT assessed between 1,5 and 3 months after treatment</measure>
    <time_frame>Between 1,5 and 3 months after inclusion</time_frame>
    <safety_issue>No</safety_issue>
    <description>The treatment efficacy is assessed by calculation of local control rate of irradiated locations according to RECIST version 1.1 criteria (complete response + partial response + stable disease) between 1,5 and 3 months after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progressive Free Survival</measure>
    <time_frame>From the date of inclusion to the date of progression</time_frame>
    <safety_issue>No</safety_issue>
    <description>Calculated from the date of inclusion to the date defined as the first documented disease progression, or second cancer appearance, or death from any cause (Up to 5 years since the first inclusion)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From the date of inclusion to the date of death (Up to 5 years since the first inclusion)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Calculated from the date of inclusion to the date of death from any cause (Up to 5 years since the first inclusion)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short time Safety profile of SBRT</measure>
    <time_frame>From inclusion to 3 months after inclusion</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Toxicities appeared during SBRT treatment and up to 3 months after SBRT. Toxicities will be assessed by the evaluation of intensity and incidence of the Adverse Events (AE) displayed by patients. The intensity of each AE will be classified according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term Safety profile of SBRT</measure>
    <time_frame>after 24 months after inclusion</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Toxicities appeared after 24 months after inclusion. The outcome measure concerns toxicities appeared after the study following period. Toxicities will be assessed by the evaluation of intensity and incidence of the Adverse Events (AE) displayed by patients. The intensity of each AE will be classified according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of SBRT assessed 12 months after treatment</measure>
    <time_frame>12 months after inclusion</time_frame>
    <safety_issue>No</safety_issue>
    <description>The treatment efficacy is assessed by calculation of local control rate of irradiated locations according to RECIST version 1.1 criteria (complete response + partial response + stable disease) at 12 months after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of SBRT assessed 24 months after treatment</measure>
    <time_frame>24 months after inclusion</time_frame>
    <safety_issue>No</safety_issue>
    <description>The treatment efficacy is assessed by calculation of local control rate of irradiated locations according to RECIST version 1.1 criteria (complete response + partial response + stable disease) at 24 months after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medium time Safety profile of SBRT</measure>
    <time_frame>Between 3 months and 24 months after inclusion</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Toxicities appeared between 3 months and 24 months after treatment. Toxicities will be assessed by the evaluation of intensity and incidence of the Adverse Events (AE) displayed by patients. The intensity of each AE will be classified according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0</description>
  </secondary_outcome>
  <other_outcome>
    <measure>SBRT treatment and toxicities related costs for 6 months after SBRT</measure>
    <time_frame>6 months after inclusion</time_frame>
    <safety_issue>No</safety_issue>
    <description>The SBRT treatment related costs will be evaluated by a &quot;microcosting&quot; method which take into account, in particular, the irradiation duration seance, the time for the mobilized staff, the kind of equipment required, the duration of related AE hospitalizations.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cost/Efficacy ratio between 2 modalities of SBRT treatment of ependymoma at 6 months after treatment</measure>
    <time_frame>6 months after inclusion</time_frame>
    <safety_issue>No</safety_issue>
    <description>2 modalities of SBRT are compared in patients with an ependymoma (3 fractions of 8 Gy versus 5 fractions of 5 Gy). It will be calculated the cost/efficacity ratio for the avoided toxicity 6 months after SBRT.
The costs will be evaluated by the data from french social security system, from homogeneous group of patients and from general classification of professional acts</description>
  </other_outcome>
  <other_outcome>
    <measure>Cost/Efficacy ratio between 2 modalities of SBRT treatment of ependymoma at 12 months after treatment</measure>
    <time_frame>12 months after inclusion</time_frame>
    <safety_issue>No</safety_issue>
    <description>2 modalities of SBRT are compared in patients with an ependymoma (3 fractions of 8 Gy versus 5 fractions of 5 Gy). It will be calculated :
the cost/efficacity per gained year of life without relapse after 12 months after SBRT
the cost/efficacity per gained year of life without disease after 12 months after SBRT.
The costs will be evaluated by the data from french social security system, from homogeneous group of patients and from general classification of professional acts</description>
  </other_outcome>
  <other_outcome>
    <measure>Cost/Efficacy ratio between 2 modalities of SBRT treatment of ependymoma at 24 months after treatment</measure>
    <time_frame>24 months after inclusion</time_frame>
    <safety_issue>No</safety_issue>
    <description>2 modalities of SBRT are compared in patients with an ependymoma (3 fractions of 8 Gy versus 5 fractions of 5 Gy). It will be calculated :
the cost/efficacity per gained year of life without relapse after 24 months after SBRT
the cost/efficacity per gained year of life without disease after 24 months after SBRT.
The costs will be evaluated by the data from french social security system, from homogeneous group of patients and from general classification of professional acts</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Brain Metastasis</condition>
  <condition>Spinal Tumors</condition>
  <condition>Lung Tumors</condition>
  <condition>Ependymoma</condition>
  <arm_group>
    <arm_group_label>SBRT treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>According to the site to irradiate and to local constraints, SBRT consist in 1 to 8 fractions of 5 to 18 Gy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT treatment</intervention_name>
    <description>For Brain metastasis the SBRT treatment consists on 3 fractions of 8 Gy or 5 fractions of 7 Gy or 1 fraction of 18 Gy for a single metastasis which is less than 20 mm.
For primary or secondary pulmonary tumors the SBRT treatment consists on 3 fractions of 15 Gy or 5 fractions of 10 Gy for peripheral lesions and on 5 fractions of 8 Gy for proximal lesions.
For primary or secondary spinal or para-spinal tumors the SBRT treatment consists on 3 fractions of 9 Gy or 5 fractions of 7 Gy.
For previously irradiated tumors (same locations) the SBRT treatment consists on 5 to 8 fractions of 5 Gy.
For relapsed Ependymoma previously irradiated the SBRT treatment will be allocated by surgical stratified randomization and consists on either 3 fractions of 8 Gy or 5 fractions of 5 Gy.</description>
    <arm_group_label>SBRT treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  18 months ≤ age ≤ 20 years

          -  Malignant primary tumor, histologically or cytologically proven

          -  Systemic disease under control or with slow evolution

          -  Written indication of SBRT according to local pediatrics meeting and national
             Radiotherapy (RT) web conference

          -  Performance Status ≤ 2 according to Eastern Cooperative Oncology Group (ECOG)

          -  Sites

               -  Brain metastasis (≤ 3 on MRI) not suitable for surgery, without hemorrhage, less
                  than 3 cm each, not in the brain stem

               -  Primary or secondary spinal/para spinal metastasis (≤ 3), not suitable for
                  surgery or with a non operable macroscopic residue, less than 5 cm

               -  Lung metastasis (≤ 3), less than 5 cm, not eligible for surgery, or macroscopic
                  residue not suitable for surgery

               -  Previously irradiated relapsing isolated primitive/secondary tumor (intra
                  cranial or extra cranial), with no possible surgery, or macroscopic residue.

          -  Affiliation to a social security scheme

          -  Signed Informed consent by patient or parents.

        IN ADDITION FOR RELAPSING EPENDYMOMA:

          -  Histologically proven local ependymoma at diagnosis

          -  Previously irradiated ependymoma

          -  Exclusive local relapse in previously irradiated site

          -  Review of operability at time of relapse by a multidisciplinary staff

          -  Relapse must be confirmed by a neuro-oncology multidisciplinary staff, on MRI
             evolutivity characteristics

          -  Time to relapse after previous irradiation ≥ 1 year

        NON-INCLUSION CRITERIA :

          -  Concomitant chemotherapy

          -  No evaluable target

          -  Pregnancy

          -  Follow-up impossible

        IN ADDITION FOR RELAPSING EPENDYMOMAS:

          -  Metastatic patient at diagnosis and/or at relapse

          -  Complete remission never obtained

        NON-RANDOMIZATION DOSIMETRIC CRITERIA (ONLY FOR EPENDYMOMA)

          -  Cumulative doses to brain stem ≥ 115 Gy

          -  Tumor volume at relapse ≥ 30 cm3

          -  Primary RT dose + Re-irradiation dose more than 112 Gy

          -  Cumulative dose to the chiasma &gt; 54 Gy

          -  Cumulative dose to any point of the brain &gt; 115 Gy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Line CLAUDE, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Léon Bérard</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Line CLAUDE, Doctor</last_name>
    <phone>+33478782652</phone>
    <email>line.claude@lyon.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christian CARRIE, Doctor</last_name>
    <phone>+33478782652</phone>
    <email>christian.carrie@lyon.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <state>Alpes Maritimes</state>
        <zip>06050</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre-Yves BONDIAU, Doctor</last_name>
      <phone>+33492031261</phone>
      <email>pierre-yves.bondiau@nice.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre-Yves BONDIAU, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juliette THARIAT, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <state>Bas-Rhin</state>
        <zip>67805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Georges NOEL, Doctor</last_name>
      <phone>+33388252471</phone>
      <email>gnoel@strasbourg.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Georges NOEL, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital La Timone</name>
      <address>
        <city>Marseille</city>
        <state>Bouches du Rhône</state>
        <zip>13500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laëtitia PADOVANI, Doctor</last_name>
      <phone>+33491384334</phone>
      <email>laetitia.padovani@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Laëtitia PADOVANI, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <state>Calvados</state>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Louis HABRAND, Doctor</last_name>
      <phone>+33231455020</phone>
      <email>jl.habrand@baclesse.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Louis HABRAND, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephan DINU, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux - Hôpital Saint André</name>
      <address>
        <city>Bordeaux</city>
        <state>Gironde</state>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aymeri HUCHET</last_name>
      <phone>+33556795679</phone>
      <email>aymeri.huchet@chu.bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Aymeri HUCHET, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Claudius Régaud</name>
      <address>
        <city>Toulouse</city>
        <state>Haute Garonne</state>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne LAPRIE, Doctor</last_name>
      <phone>+33561424188</phone>
      <email>laprie.anne@claudiusregaud.fr</email>
    </contact>
    <investigator>
      <last_name>Anne LAPRIE, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <state>Hérault</state>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christine KERR, Doctor</last_name>
      <phone>+33467613132</phone>
      <email>christine.kerr@montpellier.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Christine KERR, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75231</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claire ALAPETITE, Doctor</last_name>
      <phone>+33144324634</phone>
      <email>claire.alapetite@curie.net</email>
    </contact>
    <investigator>
      <last_name>Claire ALAPETITE, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylvie HELFRE, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <state>Ille et Vilaine</state>
        <zip>35062</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julie LESEUR, Doctor</last_name>
      <phone>+33299253042</phone>
      <email>j.leseur@rennes.fnclcc.fr</email>
    </contact>
    <investigator>
      <last_name>Julie LESEUR, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest René Gauducheau</name>
      <address>
        <city>Saint Herblain</city>
        <state>Loire Atlantique</state>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphane SUPIOT, Doctor</last_name>
      <phone>+33240679900</phone>
      <email>stephane.supiot@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphane SUPIOT, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc-André MAHE, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandoeuvre-Lès-Nancy</city>
        <state>Meurthe et Moselle</state>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Valérie BERNIER, Doctor</last_name>
      <phone>+33383598533</phone>
      <email>v.bernier@nancy.fnclcc.fr</email>
    </contact>
    <investigator>
      <last_name>Valérie BERNIER, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bernard COCHE-DEQUEANT, Doctor</last_name>
      <phone>+33320295911</phone>
      <email>b-coche@o-lambret.fr</email>
    </contact>
    <investigator>
      <last_name>Bernard COCHE-DEQUEANT, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <state>Rhône</state>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Line CLAUDE, Doctor</last_name>
      <phone>+33478782652</phone>
      <email>line.claude@lyon.unicancer.fr</email>
    </contact>
    <contact_backup>
      <last_name>Christian CARRIE, Doctor</last_name>
      <phone>+33478782652</phone>
      <email>christian.carrie@lyon.unicancer.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Line CLAUDE, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian CARRIE, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Val de Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphanie BOLLE, Doctor</last_name>
      <phone>+33142114995</phone>
      <email>stephanie.bolle@igr.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphanie BOLLE, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frédéric DHERMAIN, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Timmerman RD. An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. Semin Radiat Oncol. 2008 Oct;18(4):215-22. doi: 10.1016/j.semradonc.2008.04.001.</citation>
    <PMID>18725106</PMID>
  </reference>
  <reference>
    <citation>Zacharoulis S, Ashley S, Moreno L, Gentet JC, Massimino M, Frappaz D. Treatment and outcome of children with relapsed ependymoma: a multi-institutional retrospective analysis. Childs Nerv Syst. 2010 Jul;26(7):905-11. doi: 10.1007/s00381-009-1067-4. Epub 2009 Dec 29.</citation>
    <PMID>20039045</PMID>
  </reference>
  <reference>
    <citation>Liu AK, Foreman NK, Gaspar LE, Trinidad E, Handler MH. Maximally safe resection followed by hypofractionated re-irradiation for locally recurrent ependymoma in children. Pediatr Blood Cancer. 2009 Jul;52(7):804-7. doi: 10.1002/pbc.21982.</citation>
    <PMID>19260098</PMID>
  </reference>
  <reference>
    <citation>Combs SE, Behnisch W, Kulozik AE, Huber PE, Debus J, Schulz-Ertner D. Intensity Modulated Radiotherapy (IMRT) and Fractionated Stereotactic Radiotherapy (FSRT) for children with head-and-neck-rhabdomyosarcoma. BMC Cancer. 2007 Sep 13;7:177.</citation>
    <PMID>17854490</PMID>
  </reference>
  <reference>
    <citation>Giller CA, Berger BD, Pistenmaa DA, Sklar F, Weprin B, Shapiro K, Winick N, Mulne AF, Delp JL, Gilio JP, Gall KP, Dicke KA, Swift D, Sacco D, Harris-Henderson K, Bowers D. Robotically guided radiosurgery for children. Pediatr Blood Cancer. 2005 Sep;45(3):304-10.</citation>
    <PMID>15558704</PMID>
  </reference>
  <reference>
    <citation>Grabb PA, Lunsford LD, Albright AL, Kondziolka D, Flickinger JC. Stereotactic radiosurgery for glial neoplasms of childhood. Neurosurgery. 1996 Apr;38(4):696-701; discussion 701-2.</citation>
    <PMID>8692387</PMID>
  </reference>
  <reference>
    <citation>Flannery T, Kano H, Martin JJ, Niranjan A, Flickinger JC, Lunsford LD, Kondziolka D. Boost radiosurgery as a strategy after failure of initial management of pediatric primitive neuroectodermal tumors. J Neurosurg Pediatr. 2009 Mar;3(3):205-10. doi: 10.3171/2008.11.PEDS08268.</citation>
    <PMID>19338466</PMID>
  </reference>
  <reference>
    <citation>Conter C, Carrie C, Bernier V, Geoffray A, Pagnier A, Gentet JC, Lellouch-Tubiana A, Chabaud S, Frappaz D. Intracranial ependymomas in children: society of pediatric oncology experience with postoperative hyperfractionated local radiotherapy. Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1536-42. doi: 10.1016/j.ijrobp.2008.09.051. Epub 2009 Apr 11.</citation>
    <PMID>19362789</PMID>
  </reference>
  <reference>
    <citation>Massimino M, Gandola L, Giangaspero F, Sandri A, Valagussa P, Perilongo G, Garrè ML, Ricardi U, Forni M, Genitori L, Scarzello G, Spreafico F, Barra S, Mascarin M, Pollo B, Gardiman M, Cama A, Navarria P, Brisigotti M, Collini P, Balter R, Fidani P, Stefanelli M, Burnelli R, Potepan P, Podda M, Sotti G, Madon E; AIEOP Pediatric Neuro-Oncology Group. Hyperfractionated radiotherapy and chemotherapy for childhood ependymoma: final results of the first prospective AIEOP (Associazione Italiana di Ematologia-Oncologia Pediatrica) study. Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1336-45.</citation>
    <PMID>15050308</PMID>
  </reference>
  <reference>
    <citation>Sharma MS, Kondziolka D, Khan A, Kano H, Niranjan A, Flickinger JC, Lunsford LD. Radiation tolerance limits of the brainstem. Neurosurgery. 2008 Oct;63(4):728-32; discussion 732-3. doi: 10.1227/01.NEU.0000325726.72815.22.</citation>
    <PMID>18981883</PMID>
  </reference>
  <reference>
    <citation>Merchant TE, Boop FA, Kun LE, Sanford RA. A retrospective study of surgery and reirradiation for recurrent ependymoma. Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):87-97. doi: 10.1016/j.ijrobp.2007.09.037.</citation>
    <PMID>18406885</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 11, 2013</lastchanged_date>
  <firstreceived_date>December 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatrics</keyword>
  <keyword>SBRT</keyword>
  <keyword>Brain metastasis</keyword>
  <keyword>Pulmonary metastasis</keyword>
  <keyword>Spinal metastasis</keyword>
  <keyword>Pulmonary primary tumor</keyword>
  <keyword>Spinal primary tumor</keyword>
  <keyword>Relapsed ependymoma</keyword>
  <keyword>Relapsed irradiated tumors</keyword>
  <keyword>Local control rate</keyword>
  <keyword>Safety</keyword>
  <keyword>Overall survival</keyword>
  <keyword>Progression Free Survival</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ependymoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Spinal Cord Neoplasms</mesh_term>
    <mesh_term>Spinal Neoplasms</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
